Retrospective analysis of tigecycline shows that it may be an option for children with severe infections

• DOI: 10.1111/apa.13516
• Publication Date: 2016-07-06T07:45:16Z
• Authors: Zheng‐Yi Zhu; Ju‐Fei Yang; Ying‐Hua Ni; Wei‐Feng Ye; Jue Wang; Miao‐Lian Wu
• Keywords: Tigecycline; Acinetobacter baumannii

This study assessed the efficacy and safety of tigecycline in children with life-threatening infections.We retrospectively reviewed clinical records patients treated from June 2012 to May 2014 a Chinese tertiary centre.The comprised 24 (14 male) median age four years (range, 50 days-12 years). The most frequently isolated microorganism, common isolation site type infection were Acinetobacter baumannii, tracheal aspirate fluid ventilator-associated pneumonia, respectively. Tigecycline was administered at loading dose 1.5 or 2.0 mg/kg 1.0 every 12 hours after that. average duration treatment 11.6 ± 5.8 days. response microbiological eradication rate 37.5% 29.2%, Six we studied (25.0%) died, three these deaths considered be related. Adverse drug reactions identified (16.7%) during treatment, including abnormal liver function, prolonged prothrombin time diarrhoea.Our findings suggest that may an option for severe infections. However, more prospective, controlled trials are required objectively evaluate children.